Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

@article{Spanier1998HeparinlessCB,
  title={Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.},
  author={T B Spanier and Mehmet C. Oz and Oktavijan P. Minanov and Ronit Simantov and W. Jake Kisiel and David M. Stern and E. A. Rose and Ann Marie Schmidt},
  journal={The Journal of thoracic and cardiovascular surgery},
  year={1998},
  volume={115 5},
  pages={1179-88}
}
OBJECTIVE Cardiopulmonary bypass is a potent stimulus for activation of procoagulant pathways. Heparin, the traditional antithrombotic agent, however, is often associated with increased perioperative blood loss because of its multiple sites of action in the coagulation cascade and its antiplatelet and profibrinolytic effects. Furthermore, heparin-mediated immunologic reactions (that is, heparin-induced thrombocytopenia) may contraindicate its use. Cardiopulmonary bypass with a selective factor… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Anticoagulant therapy during cardiopulmonary bypass

Journal of Thrombosis and Thrombolysis • 2008
View 4 Excerpts
Highly Influenced

Pharmacologic strategies for combating the inflammatory response.

The journal of extra-corporeal technology • 2007
View 1 Excerpt

Heparinless cardiopulmonary bypass with argatroban in dogs.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery • 2004

Similar Papers

Loading similar papers…